[abstract] DOES HYPERBARIC OXYGEN POTENTIATE PROSTATE CANCER GROWTH OR RECURRENCE?

Rubicon Research Repository/Manakin Repository

[abstract] DOES HYPERBARIC OXYGEN POTENTIATE PROSTATE CANCER GROWTH OR RECURRENCE?

Show simple item record


dc.contributor.author Hampson, NB en_US
dc.contributor.author O'Reilly, KJ en_US
dc.contributor.author Geddeis, L en_US
dc.contributor.author Corman, JM en_US
dc.date.accessioned 2006-08-01T21:11:51Z
dc.date.available 2006-08-01T21:11:51Z
dc.date.issued 2001 en_US
dc.identifier.other Undersea Hyp Med 2001 en_US
dc.identifier.uri http://archive.rubicon-foundation.org/895
dc.description Undersea and Hyperbaric Medical Society, Inc. (http://www.uhms.org ) en_US
dc.description.abstract Introduction: External beam radiation therapy is a common treatment for prostate cancer, although it results in hemorrhagic cystitis in up to 5percent of patients. Hyperbaric oxygen (HBO2) is effective therapy for radiation-induced hemorrhagic cystitis. Because the mechanism of action of HBO2 is via angiogenesis, the effect on the underlying malignancy is of great interest. This patient population is ideally suited to examine whether HBO2 has an effect on tumor growth. The purpose of our study was to assess the rate of prostate cancer growth or recurrence after HBO2 therapy administered for radiation-induced cystitis. Methods: Medical records of patients who received HBO2 for radiation-induced cystitis at our institution from 1988-1998 were retrospectively reviewed. Inclusion criteria for this study included a prior diagnosis of prostate cancer treated primarily with external beam radiation. In such patients, prostate specific antigen (PSA) levels prior to and following HBO2 were reviewed. Results: Of 49 patients treated for radiation-induced hemorrhagic cystitis, 36 received their radiation therapy for prostate cancer. Among those 36 patients, 8 had sufficient PSA data available for review. The mean age at diagnosis of prostate cancer was 69 years (range 55-79). The mean time from radiation therapy until HBO2 was 65 months (range 26-134). Pt. PSA Velocity Pre-HBO2 PSA Velocity Post-HBO2, 1 1.9 (ng/ml/yr) 0.0 (ng/ml/yr), 2 0.0 0.0, 3 0.0 0.0, 4 1.0 1.5, 5 0.4 0.1, 6 0.0 0.0, 7 0.0 0.0, 8 2.0 1.8, Conclusions: Our results demonstrate no evidence of disease recurrence in four patients with stable disease pre-HBO2. Furthermore, in four patients with progressive disease prior to HBO2, three (75percent) had no increase in PSA velocity following therapy. Further evaluation of the impact of HBO2 on the growth of prostate cancer is indicated. en_US
dc.language.iso en_US
dc.rights Undersea and Hyperbaric Medical Society, Inc. (http://www.uhms.org ) en_US
dc.subject cystitis en_US
dc.subject radionecrosis en_US
dc.subject radiation en_US
dc.subject hyperbaric en_US
dc.title [abstract] DOES HYPERBARIC OXYGEN POTENTIATE PROSTATE CANCER GROWTH OR RECURRENCE? en_US

Files in this item

Files Size Format View
abstract.txt 259bytes Text file View/Open

This item appears in the following Collection(s)

  • UHMS Meeting Abstracts
    This is a collection of the published abstracts from the Undersea and Hyperbaric Medical Society (UHMS) annual meetings.

Show simple item record

Browse

My Account